Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell Lymphoma
Latest Information Update: 08 Mar 2024
At a glance
- Drugs Azacitidine (Primary) ; Etoposide (Primary) ; Lenalidomide (Primary) ; Pegaspargase (Primary) ; Tislelizumab (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 29 Feb 2024 Status changed from recruiting to completed.
- 01 Oct 2021 New trial record